https://doi.org/10.4081/monaldi.2021.1876
Predictors of severity and in-hospital mortality in patients with influenza
Submitted: April 3, 2021
Accepted: July 20, 2021
Published: August 10, 2021
Accepted: July 20, 2021
Abstract Views: 1329
PDF: 515
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Influenza virus is a common agent of acute respiratoty infections during epidemic periods. It is a major cause of morbidity and mortality and represent a significant burden on the healthcare system. We aimed to evaluate predictors of severity and of in-hospital mortality in patients hospitalized with influenza infection. We performed a retrospective cohort study of hospitalized, laboratory confirmed cases of influenza disease in Centro Hospitalar de São João between October 2016-May 2017 and October 2017-May 2018. The endpoints being analysed were severity and in-hospital mortality. A multivariate logistic regression analysis was used to determine independent predictors of severity and of in-hospital mortality. We studied 221 hospitalized influenza infection cases. Mean age 66±16 years, 57.9% were male, thirty-seven patients (16.7%) died in-hospital and 101 patients (45.7%) met severity criteria. C-reactive protein (CRP) was the only independent predictor of severity as well as the only independent predictor of higher in-hospital mortality in patients admitted due to influenza infection. Multivariate-adjusted CRP OR for severity was 1.10, 95% CI 1.06-1.15 per each 10 mg/L increase in CPR and for in-hospital mortality risk the OR was of 1.05, 95% CI 1.01-1.09, p=0.01, per each 10 mg/L increase. Concluding, in patients’ hospital-admitted due to influenza infection CRP was the only predictor of severity with a 10% increased risk of inotropic support/ventilatory support/prolonged hospitalization needs and a 5% increase risk of in-hospital death per each 10 mg/l increase.
Center for Disease Control and Prevention. Seasonal influenza (flu). Accessed: 01/06/2019. Available from: https://www.cdc.gov/flu/about/index.html
Uyeki TM. Influenza. Ann Intern Med 2017;167:ITC33-48.
Bresee J, Hayden FG. Epidemic influenza-responding to the expected but unpredictable. N Engl J Med 2013;368:589.
DOI: https://doi.org/10.1056/NEJMp1300375
European Centre for Disease Prevention and Control. Influenza virus characterisation, summary Europe, September 2018. Stockholm: ECDC; 2018.
Instituto Nacional de Saúde Doutor Ricardo Jorge I.P. [Boletim de Vigilância Epidemiológica da Gripe, Época 2016/2017 - Semana 20].[in Portuguese]. Instituto Nacional de Saúde Doutor Ricardo Jorge I.P., 2017.
Instituto Nacional de Saúde Doutor Ricardo Jorge I.P. [Boletim de Vigilância Epidemiológica da Gripe, Época 2017-2018 - Semana 20].[in Portuguese]. Instituto Nacional de Saúde Doutor Ricardo Jorge I.P., 2018.
Chaves SS, Aragon D, Bennett N, et al. Patients hospitalized with laboratory-confirmed influenza during the 2010-2011 influenza season: exploring disease severity by virus type and subtype. J Infect Dis 2013;208:1305-14.
DOI: https://doi.org/10.1093/infdis/jit316
Ribeiro AF, Pellini AC, Kitagawa BY, et al. Risk factors for death from Influenza A(H1N1)pdm09, State of Sao Paulo, Brazil, 2009. PLoS One 2015;10:e0118772.
Arriola C, Garg S, Anderson EJ, et al. Influenza vaccination modifies disease severity among community-dwelling adults hospitalized with influenza. Clin Infect Dis 2017;65:1289-97.
DOI: https://doi.org/10.1093/cid/cix468
Center for Disease Control and Prevention. Prevent flu. Accessed: 01/06/2019. Available from: https://www.cdc.gov/flu/prevent/vaccinations.htm
Ghebrehewet S, MacPherson P, Ho A. Influenza. BMJ 2016;355:i6258.
Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005;353:1363-73.
DOI: https://doi.org/10.1056/NEJMra050740
Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235.
DOI: https://doi.org/10.1136/bmj.326.7401.1235
Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015;385:1729.
DOI: https://doi.org/10.1016/S0140-6736(14)62449-1
Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet 2006;367:303.
DOI: https://doi.org/10.1016/S0140-6736(06)67970-1
Hong KW, Cheong HJ, Choi WS, et al. Clinical courses and outcomes of hospitalized adult patients with seasonal influenza in Korea, 2011–2012: hospital-based influenza morbidity & mortality (HIMM) surveillance. J Infect Chemother 2014;29:9–14.
DOI: https://doi.org/10.1016/j.jiac.2013.07.001
Canak G, Kovacevic N, Turkulov V, et al. Clinical features, treatments and the outcomes of influenza A (H1N1) 2009 among the hospitalized patients in the clinic for infectious diseases in Novi Sad. Vojnosanit Pregl 2013;70:155–62.
DOI: https://doi.org/10.2298/VSP1302155C
Baden LR, Swaminathan S, Angarone M, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2016;14:882-913.
DOI: https://doi.org/10.6004/jnccn.2016.0093
Vasileva D, Badawi A. C-reactive protein as a biomarker of severe H1N1 influenza. Inflamm Res 2019;68:39–46.
DOI: https://doi.org/10.1007/s00011-018-1188-x
Zimmerman O, Rogowski O, Aviram G, et al. C-reactive protein serum levels as an early predictor of outcome in patients with pandemic H1N1 influenza A virus infection. BMC Infect Dis 2010;10:288.
DOI: https://doi.org/10.1186/1471-2334-10-288
Gao RB, Wang L, Bai T, et al. C-reactive mediating immunopathological lesions: a potential treatment option for severe influenza A diseases. EBioMedicine 2017;22:133–42.
DOI: https://doi.org/10.1016/j.ebiom.2017.07.010
Liu Q, Zhou YH, Yang ZQ. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol 2016;13:3–10.
DOI: https://doi.org/10.1038/cmi.2015.74
Shah SH, Newby LK. C-reactive protein: a novel marker of cardiovascular risk. Cardiol Rev 2003;11:169-79.
DOI: https://doi.org/10.1097/01.CRD.0000077906.74217.6E
Supporting Agencies
not applicableHow to Cite
Serino, Mariana, Nuno Melo, João Paulo Caldas, Ana Ferreira, David Garcia, and Patrícia Lourenço. 2021. “Predictors of Severity and in-Hospital Mortality in Patients With Influenza”. Monaldi Archives for Chest Disease 92 (1). https://doi.org/10.4081/monaldi.2021.1876.
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Federico Raimondi, Stefano Centanni, Fabrizio Luppi, Stefano Aliberti, Francesco Blasi, Paola Rogliani, Claudio Micheletto, Marco Contoli, Alessandro Sanduzzi Zamparelli, Marialuisa Bocchino, Paolo Busatto, Luca Novelli, Simone Pappacena, Luca Malandrino, Giorgio Lorini, Greta Cairoli, Fabiano Di Marco, Respiratory rate-oxygenation index on the 3rd day is the best predictor of treatment failure in COVID-19 patients , Monaldi Archives for Chest Disease: Early Access
- Anshul Mittal, Pranav Ish, Vidushi Rathi, Satish Kumar Kumawat, Shibdas Chakrabarti, JC Suri, Rehabilitation in obstructive sleep apnea: an ignored treatment adjunct , Monaldi Archives for Chest Disease: Early Access
- Nedia Moussa , Rahma Gargouri, Mouna Snoussi, Rym Khemakhem, Zouhir Bahloul, Samy Kammoun, Nonspecific interstitial pneumonia revealing an antisynthetase syndrome , Monaldi Archives for Chest Disease: Vol. 93 No. 3 (2023)
- Amitesh Gupta, Eshutosh Chandra, Shipra Anand, Naresh Kumar, Richa Arora, Divyanshi Rana, Parul Mrigpuri, Latent tuberculosis diagnostics: current scenario and review , Monaldi Archives for Chest Disease: Early Access
- Manu Dogra, Surabhi Jaggi, Deepak Aggarwal, Seema Gupta, Varinder Saini, Jasbinder Kaur, Role of interleukin-6 and insulin resistance as screening markers for metabolic syndrome in patients of chronic obstructive pulmonary disease. A hospital-based cross-sectional study , Monaldi Archives for Chest Disease: Vol. 92 No. 3 (2022)
- Alfonso Sforza, Maria Viviana Carlino, Mario Guarino, Ilaria Fucile, Nicola De Luca, Costantino Mancusi, Diagnostic accuracy of inferior vena cava evaluation in the diagnosis of acute heart failure among dyspneic patients , Monaldi Archives for Chest Disease: Vol. 90 No. 4 (2020)
- Nicholas Zareifopoulos, Maria Lagadinou, Anastasia Karela, Christina Platanaki, Gerasimos Karantzogiannis, Dimitrios Velissaris, Management of COVID-19: the risks associated with treatment are clear, but the benefits remain uncertain , Monaldi Archives for Chest Disease: Vol. 90 No. 2 (2020)
- Siddharth Raj Yadav, Rohit Kumar, Amit Kumar, Pranav Ish, Nitesh Gupta, Shibdas Chakrabarti, Sleepless in COVID-19: how not to lose sleep in lockdowns , Monaldi Archives for Chest Disease: Vol. 90 No. 2 (2020)
- Tarun Krishna Boppana, Saurabh Mittal, Karan Madan, Anant Mohan, Vijay Hadda, Randeep Guleria, Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials , Monaldi Archives for Chest Disease: Vol. 92 No. 4 (2022)
- Caterina Oriana Aragona, Andrea Bianco, Roberto Caruso, Massimo Cerulli, Nicola Cosentino, Antonio Cittadini, Michele Gabriele, Mario Mallardo, Roberto Marini, Bruna Miserrafiti, Pietro Palermo, Alfonso Galati, Lipid-lowering therapy in patients with coronary heart disease: an Italian real-life survey. Results from the Survey on Risk FactOrs and CardiovascuLar secondary prEvention and drug strategieS (SOFOCLES) in Italy , Monaldi Archives for Chest Disease: Early Access
<< < 33 34 35 36 37 38 39 40 41 42 > >>
You may also start an advanced similarity search for this article.
